122 related articles for article (PubMed ID: 34638347)
1. Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis.
Claudiani S; Mason CC; Milojkovic D; Bianchi A; Pellegrini C; Di Marco A; Fiol CR; Robinson M; Ponnusamy K; Mokretar K; Chowdhury A; Albert M; Reid AG; Deininger MW; Naresh K; Apperley JF; Khorashad JS
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638347
[TBL] [Abstract][Full Text] [Related]
2. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.
Yan D; Pomicter AD; Tantravahi S; Mason CC; Senina AV; Ahmann JM; Wang Q; Than H; Patel AB; Heaton WL; Eiring AM; Clair PM; Gantz KC; Redwine HM; Swierczek SI; Halverson BJ; Baloglu E; Shacham S; Khorashad JS; Kelley TW; Salama ME; Miles RR; Boucher KM; Prchal JT; O'Hare T; Deininger MW
Clin Cancer Res; 2019 Apr; 25(7):2323-2335. PubMed ID: 30563936
[TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib for the treatment of myelofibrosis: its clinical potential.
Ostojic A; Vrhovac R; Verstovsek S
Ther Clin Risk Manag; 2012; 8():95-103. PubMed ID: 22399854
[TBL] [Abstract][Full Text] [Related]
4. Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis.
Bewersdorf JP; Jaszczur SM; Afifi S; Zhao JC; Zeidan AM
Cancer Manag Res; 2019; 11():10777-10790. PubMed ID: 31920387
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2.
Ishida S; Akiyama H; Umezawa Y; Okada K; Nogami A; Oshikawa G; Nagao T; Miura O
Oncotarget; 2018 Jun; 9(42):26834-26851. PubMed ID: 29928488
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells.
Akiyama H; Umezawa Y; Watanabe D; Okada K; Ishida S; Nogami A; Miura O
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32050632
[TBL] [Abstract][Full Text] [Related]
7. Clinical potential of pacritinib in the treatment of myelofibrosis.
Duenas-Perez AB; Mead AJ
Ther Adv Hematol; 2015 Aug; 6(4):186-201. PubMed ID: 26288713
[TBL] [Abstract][Full Text] [Related]
8. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A
Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
[TBL] [Abstract][Full Text] [Related]
9. Exploring redox vulnerabilities in JAK2
Lima K; Lopes LR; Machado-Neto JA
Hematol Transfus Cell Ther; 2021; 43(4):430-436. PubMed ID: 32962959
[TBL] [Abstract][Full Text] [Related]
10. Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms.
Bose P; Masarova L; Verstovsek S
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33050168
[TBL] [Abstract][Full Text] [Related]
11. [Research Progress on Effect of JAK Inhibitors on Myelofibrosis- Review].
Liu JX; Chen W; Xu KL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):283-286. PubMed ID: 29397859
[TBL] [Abstract][Full Text] [Related]
12. Janus Kinase V617F Mutation Detection in Patients with Myelofibrosis.
Nikolova D; Yordanov A; Damyanova V; Radinov A; Toncheva D
Balkan J Med Genet; 2019 Jun; 22(1):57-60. PubMed ID: 31523621
[TBL] [Abstract][Full Text] [Related]
13. Distinct profile of CD34
Forte D; Barone M; Morsiani C; Simonetti G; Fabbri F; Bruno S; Bandini E; Sollazzo D; Collura S; Deregibus MC; Auteri G; Ottaviani E; Vianelli N; Camussi G; Franceschi C; Capri M; Palandri F; Cavo M; Catani L
J Exp Clin Cancer Res; 2021 Feb; 40(1):49. PubMed ID: 33522952
[TBL] [Abstract][Full Text] [Related]
14. A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis.
Palandri F; Palumbo GA; Bonifacio M; Elli EM; Tiribelli M; Auteri G; Trawinska MM; Polverelli N; Benevolo G; Tieghi A; Cavalca F; Caocci G; Beggiato E; Binotto G; Cavazzini F; Miglino M; Bosi C; Crugnola M; Bocchia M; Martino B; Pugliese N; Venturi M; Isidori A; Cattaneo D; Krampera M; Pane F; Cilloni D; Semenzato G; Lemoli RM; Cuneo A; Abruzzese E; Branzanti F; Vianelli N; Cavo M; Heidel F; Iurlo A; Breccia M
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894394
[TBL] [Abstract][Full Text] [Related]
15. Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.
Pinilla-Ibarz J; Sweet KL; Corrales-Yepez GM; Komrokji RS
Onco Targets Ther; 2016; 9():4937-57. PubMed ID: 27570458
[TBL] [Abstract][Full Text] [Related]
16. Clinical and laboratory features of myelofibrosis and limitations of current therapies.
Gregory SA; Mesa RA; Hoffman R; Shammo JM
Clin Adv Hematol Oncol; 2011 Sep; 9(9 Suppl 22):1-16. PubMed ID: 22362131
[TBL] [Abstract][Full Text] [Related]
17. Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis.
Barosi G; Rosti V; Gale RP
Onco Targets Ther; 2015; 8():1091-102. PubMed ID: 26056473
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of Low-Dose Splenic Irradiation prior to Reduced-Intensity Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Elderly Patients with Myelofibrosis.
Matsubara E; Yamanouchi J; Kitazawa R; Azuma T; Fujiwara H; Hato T; Yasukawa M
Case Rep Hematol; 2016; 2016():8751329. PubMed ID: 27840748
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting.
Duminuco A; Nardo A; Garibaldi B; Vetro C; Longo A; Giallongo C; Di Raimondo F; Palumbo GA
J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36556033
[TBL] [Abstract][Full Text] [Related]
20. BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.
Verstovsek S; Al-Ali HK; Mascarenhas J; Perkins A; Vannucchi AM; Mohan SR; Scott BL; Woszczyk D; Koschmieder S; García-Delgado R; László R; McGreivy JS; Rothbaum WP; Kiladjian JJ
Future Oncol; 2022 Nov; ():. PubMed ID: 36416118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
